Validation batch size

Three different batch sizes were used, namely =400, =800, respectively =1200 kg in the chemical industry it is standard practice to validate a process for the available kettles and then adjust the particular batch size (minimum filling so the stirrer bar remains covered, maximum filling so no overpressure occurs and vents stay free) to achieve the requested tonnage often, campaigns of batches are run before the equipment is cleaned and refitted for the next product, see batch numbers 19. .. 23, followed by 1,. ... ... 

All these examples require that a variety of production methods are mapped with different validities in the model. The differentiation may refer to the use of different resources, dynamic material factors, modified offset times or various batch sizes. 

Minimal bounds on the production quantity are most often process dependent. Typically, a minimal campaign length is required if for example a critical mass is necessary to initiate a chemical reaction. The same is valid for maximal bounds on the production quantity. The rationale here is that a cleaning operation may be required every time a certain amount has been produced. Finally, batch size restrictions often arise in the chemical industry, if for example the batch size is determined by a reactor load or, as discussed above, the processing time for a certain production step is independent of the amount of material processed. In these scenarios, when working with model formulations using a discrete time scale, it is important that the model formulation takes into account that lot sizes may comprise of production in several adjacent periods. 

Duration of fill Depends on batch size maximum time based on media fill validation hours... 

Changes in Batch Size Postapproval changes in the size of a batch from the pilot scale used to manufacture product for clinical trials to larger or smaller commercial batch sizes require submission of additional information in the apphcation. Scale-down below 100,000 dosage units is not covered by this guidance. All scale-up changes should be properly validated and, where needed, inspected by appropriate FDA personnel. 

Postpreparative Stability. The stability of processed samples, including the resident time in the autosampler, should be determined. The stability of the drug and the internal standard should be assessed over the anticipated run time for the batch size in validation samples by determining concentrations on the basis of original calibration standards. Reinjection reproducibility should be evaluated to determine if an analytical run could be reanalyzed in the case of instrument failure. 

Significant change in batch size from what was validated and that affects the operation of or selection of manufacturing equipment... 

This guidance iccoimnends that the minimum batch size for the NDA pivotal clinical trial batch or the ANDA/AADA biobatch be at least 100 kg or 10% of a production batch, whichever is larger. Deviations from this recommendation should be discussed with the appropriate agency review division. All scale changes should be properly validated and may be inspected by appropriate agency personnel. 

Process optimization Process demonstration Process validation program Product/process certification 100 X batch size... 

Drug D may be produced in both 1000- and 2000-gal batches to meet inventory requirements. Major equipment and operator instructions are the same regardless of batch size. The only difference is the amount of each ingredient charged to the make tank. With a formulation such as this, there is little likelihood that batch size is an important process variable. Nevertheless, we will be conservative and treat each size batch as a unique process. An alternative strategy would be to validate the 2000-gal process and demonstrate for the 1000-gal batch the adequacy of mixing, using, for instance, assay data. 

Statistically evaluate the data from the validation effort. Compare the data with the specification limits listed in the protocol. Conformance to these limits is essential, because this effort must also include the determination of whether failure signifies a missing link in the scientists s understanding of the process. This exercise is especially important when the size of the validation batch is significantly larger than the largest development batch made to date. 

This approach would seem to be an example of concurrent PV [14], which fits well when the development function continues its effort to validate clinical manufacturing processes. It is also an opportunity to validate a process when it is used to produce different batch sizes with a given piece of equipment. It may even be possible to employ differently sized equipment (to make different batch sizes) as part of the validation effort. It remains to be determined whether this kind of approach ought to be extended to the commercial validation effort. Later in this chapter I will discuss the possibility, which should be attractive for the company that is totally involved in TQM. 

In many cases, because of the uncertainty about the subsequent product, companies often choose to use the worst-case following product, which would be the product having the smallest batch size and the largest daily dose for calculation purposes. In that case, the limit would be valid no matter what product is subsequently introduced in the manufacturing sequence and the company could go ahead and finish its cleaning validation study. 

Once the stage has been reached at which the product has been developed and the formulation and batch size determined, it is time for validation of the manufacturing process and the cleaning process. By that... 

Regarding batch size and scale-up, a minimum batch size of 10% of the proposed commercial production batch should be used for producing test batches of solid, oral dosage nonantibiotic products. All scale-up procedures should be validated. It is important to keep in mind that the scale-up process should not result in a change in the method of manufacture. 

As the batch-to-batch consistency study is usually the last step preceding the release of the drug product onto the market, it is essential at this time that the batches be manufactured as normal production runs. In particular, production timing should be respected and the validation batches should be full scale or at least representative of the size range of the commercial batches. 

Fig. 2 Batch size, development efforts, and extent of validation.

Physicochemical properties of raw materials and the finished dosage form should be characterized before any scale-up effort. Having methodology available and validated to compare batches is essential. For example, drug-release profiles and viscosities have the potential of being altered in scale-up by manufacturing procedures and equipment. Care must be exercised to maintain the desired profiles and other product specifications. The effect of batch size and process scale-up should be monitored closely. 

During preapproval inspection, the FDA accepts a process-validation protocol based on the company s commitment to complete successfully three production-size validation batches prior to product launch. In some situations a prevalidation (process demonstration qualification) production-size batch is completed before the entire formal three-batch program is carried out. 

The batches should be of the same size, and should be the same as the batch size intended in full-scale production. Where this is not possible, the reduced batch size should be considered in the design of the protocol and when full-scale production starts, the validity of any assumptions made should be demonstrated. 

Has the manufacturing method for each standard batch size been validated ... 

Specifications for the finished product Two specifications at release and end of shelf-life List general characteristics, specific standards tests and limits for results for the finished product must be provided Analytical test procedures described (physicochemical properties, identity of API) Quantitative determination of active, deviations, purity tests, pharmaceutical tests, colouring antimicrobial or chemical preservatives, results of validation studies, comments on the choice of routine tests and standards provided Copy of pharmacopoeia monograph and verification data Results of batch analysis (inc. date of manufacture, place of manufacture, batch size and use of batch tested) ... 

---